Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals
- PMID: 37565645
- DOI: 10.1002/jmv.28989
Ancestral SARS-CoV-2 and Omicron BA.5-specific neutralizing antibody and T-cell responses after Omicron bivalent booster vaccination in previously infected and infection-naive individuals
Abstract
Coronavirus disease-2019 (COVID-19) bivalent ancestral/Omicron messenger RNA (mRNA) booster vaccinations became available to boost and expand the immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron infections. In a prospective cohort study including 59 healthcare workers, we assessed SARS-CoV-2 ancestral and Omicron BA.5-specific neutralizing antibody and T-cell responses in previously infected and infection-naive individuals. Also, we assessed the effect of an ancestral/Omicron BA.1 bivalent mRNA booster vaccination on these immune responses. 10 months after previous monovalent mRNA vaccinations, ancestral SARS-CoV-2 S1-specific T-cell and anti-RBD IgG responses remained detectable in most individuals and a previous SARS-CoV-2 infection was associated with increased T-cell responses. T-cell responses, anti-RBD IgG, and Omicron BA.5 neutralization activity increased after receiving an ancestral/Omicron BA.1 bivalent booster mRNA vaccination. An Omicron BA.5 infection in addition to bivalent vaccination, led to a higher ratio of Omicron BA.5 to ancestral strain neutralization activity compared to no bivalent vaccination and no recent SARS-CoV-2 infection. In conclusion, SARS-CoV-2 T-cell and antibody responses persist for up to 10 months after a monovalent booster mRNA vaccination. An ancestral/Omicron BA.1 bivalent booster mRNA vaccination increases these immune responses and also induces Omicron BA.5 cross-neutralization antibody activity. Finally, our data indicate that hybrid immunity is associated with improved preservation of T-cell immunity.
Keywords: COVID-19; Omicron; SARS-CoV-2; T-cells; antibodies; vaccination.
© 2023 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.
Similar articles
-
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.Lancet Infect Dis. 2023 Aug;23(8):901-913. doi: 10.1016/S1473-3099(23)00140-8. Epub 2023 Apr 21. Lancet Infect Dis. 2023. PMID: 37088096 Free PMC article. Clinical Trial.
-
Prior SARS-CoV-2 infection affects adaptive immune responses to Omicron BA.4/BA.5 mRNA booster.J Allergy Clin Immunol. 2025 Jun;155(6):2038-2051. doi: 10.1016/j.jaci.2025.02.026. Epub 2025 Mar 3. J Allergy Clin Immunol. 2025. PMID: 40044048
-
Enhancing Omicron Sublineage Neutralization: Insights From Bivalent and Monovalent COVID-19 Booster Vaccines and Recent SARS-CoV-2 Omicron Variant Infections.Influenza Other Respir Viruses. 2024 Oct;18(10):e70000. doi: 10.1111/irv.70000. Influenza Other Respir Viruses. 2024. PMID: 39377176 Free PMC article.
-
Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.Epidemiol Prev. 2023 Nov-Dec;47(6):331-343. doi: 10.19191/EP23.6.A626.081. Epidemiol Prev. 2023. PMID: 38314543 Review. English.
-
Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron.Cytokine Growth Factor Rev. 2023 Apr;70:13-25. doi: 10.1016/j.cytogfr.2023.03.001. Epub 2023 Mar 5. Cytokine Growth Factor Rev. 2023. PMID: 36948931 Free PMC article. Review.
Cited by
-
Bivalent Omicron BA.1 vaccine booster increases memory B cell breadth and neutralising antibodies against emerging SARS-CoV-2 variants.EBioMedicine. 2024 Dec;110:105461. doi: 10.1016/j.ebiom.2024.105461. Epub 2024 Nov 28. EBioMedicine. 2024. PMID: 39612651 Free PMC article.
-
SARS-CoV-2-specific cellular and humoral immunity after bivalent BA.4/5 COVID-19-vaccination in previously infected and non-infected individuals.Nat Commun. 2024 Apr 9;15(1):3077. doi: 10.1038/s41467-024-47429-8. Nat Commun. 2024. PMID: 38594497 Free PMC article.
References
REFERENCES
-
- Xia S, Wang L, Zhu Y, Lu L, Jiang S. Origin, virological features, immune evasion and intervention of SARS-CoV-2 Omicron sublineages. Signal Transduct Target Ther. 2022;7:241. doi:10.1038/s41392-022-01105-9
-
- World Health Organization. COVID-19 Weekly Epidemiological Update 135. 2023.
-
- Doll MK, Waghmare A, Heit A, et al. Acute and postacute COVID-19 outcomes among immunologically naive adults during delta vs omicron waves. JAMA Netwk Open. 2023;6(2):e231181. doi:10.1001/jamanetworkopen.2023.1181
-
- Looi MK. How are covid-19 symptoms changing? BMJ. 2023;380:3. doi:10.1136/bmj.p3
-
- Bahremand T, Yao JA, Mill C, Piszczek J, Grant JM, Smolina K. COVID-19 hospitalisations in immunocompromised individuals in the Omicron era: a population-based observational study using surveillance data in British Columbia, Canada. Lancet Regional Health - Am. 2023;20:100461. doi:10.1016/j.lana.2023.100461
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous